Pieris Pharmaceuticals

Palvella Therapeutics, a rare disease biopharmaceutical company, debuts on Nasdaq as PVLA with $80M cash, aiming to advance QTORIN™ rapamycin for microcystic LMs and cutaneous VMs, potentially becoming the first approved therapy for these conditions.

Palvella Therapeutics, Inc. merged with Pieris Pharmaceuticals, Inc., forming a unified company under the name Palvella Therapeutics, Inc. The new company will trade on Nasdaq under the ticker symbol “PVLA” starting December 16, 2024. Led by CEO Wes Kaupinen, Palvella focuses on rare disease biopharmaceuticals, with a late-stage clinical pipeline including QTORIN™ rapamycin for microcystic lymphatic malformations and cutaneous venous malformations. Backed by $80 million in cash, the company aims to fund operations into 2027 and expand its QTORIN™ platform.

The provided content does not contain any text to summarize.

Palvella Therapeutics initiates Phase 3 trial, SELVA, evaluating QTORIN™ rapamycin for microcystic lymphatic malformations, aiming to be the first approved therapy in the U.S. for this rare, debilitating disease.

Palvella Therapeutics receives $2.6 million FDA grant for Phase 3 SELVA trial of QTORIN™ rapamycin for microcystic lymphatic malformations, highlighting unmet medical need and potential as first approved therapy.

Palvella Therapeutics receives $2.6M FDA grant for Phase 3 SELVA trial of QTORIN™ rapamycin for microcystic lymphatic malformations, highlighting unmet medical need and potential as first approved therapy.

R.A.S., M.S.T., C.Y., R.N., H.S.R., M.D., A.J.C., E.S.-R., J.C.B., C.O., K.K., A.D.E., C.V., N.W., K.S.A., A.S.C., C.F., C.I., A.T., J.T., K.Y., L.H., K.G., F.M.H., T.S., A.L.A., P.B., P.N., G.L.H., W.F.S., J.P., P.P., A.D.M., D.Y., L.J.v.V., N.M.H., L.J.E. report various institutional research funding, advisory roles, consultancy, honoraria, patents, and stock ownership.